Gefitinib (Gef, Iressa), a small molecule EGFR tyrosine kinase inhibitor, is one of the classical first-line treatment drugs that can benefit certain patients with EGFR-mutatant NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.